All In Biotech

Drug Trial Radar · NCT07323784

A Study of NTX-1472 in Social Anxiety Disorder

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Newleos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests

Conditions

  • Social Anxiety Disorder (SAD)

Interventions

  • NTX-1472Drug

    Daily (QD) x 8 weeks.

  • PlaceboDrug

    Daily (QD) x 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Baseline to Week 8

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • SOAR Clinical Study Site

    Encino, California · Recruiting

  • SOAR Clinical Study Site

    Los Angeles, California · Recruiting

  • SOAR Clinical Study Site

    Oceanside, California · Recruiting

  • SOAR Clinical Study Site

    San Jose, California · Recruiting

  • SOAR Clinical Study Site

    Jacksonville, Florida · Recruiting

  • SOAR Clinical Study Site

    Tampa, Florida · Recruiting

  • SOAR Clinical Study Site

    Boston, Massachusetts · Recruiting

  • SOAR Clinical Study Site

    Las Vegas, Nevada · Active not recruiting

  • SOAR Clinical Study Site

    Brooklyn, New York · Recruiting

  • SOAR Clinical Study Site

    Memphis, Tennessee · Recruiting

  • SOAR Clinical Study Site

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.